간섬유증 치료제 시장 : 약제 클래스별, 작용 기전, 투여 경로, 유통 채널별 - 세계 예측(2026-2032년)

The Liver Fibrosis Drugs Market was valued at USD 17.12 billion in 2025 and is projected to grow to USD 18.83 billion in 2026, with a CAGR of 10.15%, reaching USD 33.70 billion by 2032.

An authoritative introduction to the evolving therapeutic, regulatory, and commercial context shaping liver fibrosis drug development and stakeholder priorities

Liver fibrosis occupies a pivotal intersection of unmet clinical need, scientific innovation, and commercial opportunity. Over the past decade, advances in understanding wound healing, extracellular matrix remodeling, and immunometabolism have reframed fibrotic progression as a tractable therapeutic target rather than an inexorable clinical endpoint. This paradigm shift has catalyzed more diverse therapeutic modalities, encourages cross-disciplinary collaboration between hepatology and immunology experts, and elevates the importance of translational biomarkers that link mechanism to clinical outcomes.

Clinicians, payers, and developers now converge on common priorities: improving diagnostic precision, intervening earlier in the disease course, and demonstrating durable reversal of fibrosis while ensuring safety for chronic administration. Concurrently, regulatory agencies are signaling a willingness to engage on novel endpoints and adaptive trial designs, contingent on rigorously validated surrogate measures. These dynamics create a complex environment where scientific promise must be balanced against operational realities such as supply chain resilience and reimbursement pathways.

Throughout this report, emphasis is placed on how emerging therapies, platform technologies, and stakeholder incentives interact to shape development strategies. The intent is to provide a clear, actionable synthesis that supports decision-makers who must navigate scientific complexity, regulatory nuance, and commercial imperatives simultaneously.

How scientific breakthroughs, modality expansion, and innovative trial designs are driving a fundamental transformation in liver fibrosis therapeutic strategies and stakeholder behavior

The liver fibrosis landscape is undergoing transformative shifts driven by scientific breakthroughs, modality diversification, and changes in clinical trial architecture. Molecular deconvolution of fibrogenic signaling networks has enabled more precise target identification, while advances in biologics, cell and gene therapies, and small molecule design have expanded the therapeutic toolkit. As modalities diversify, developers are increasingly matching mechanism to disease phenotype, prioritizing agents that modulate core drivers of fibrogenesis rather than broadly suppressing associated inflammation.

Clinical development is also being reshaped by innovations in trial design and patient identification. Noninvasive diagnostics and digital biomarkers are enabling earlier enrollment and more efficient assessment of biological effect. These tools facilitate shorter, more informative proof-of-concept studies that reduce risk and accelerate go/no-go decisions. At the same time, partnerships across industry, academia, and contract research organizations are growing in importance as teams combine complementary expertise and capabilities to address complex translational challenges.

Commercially, pricing and access strategies are evolving in tandem with therapeutic differentiation. Payers are focusing on value demonstration through real-world evidence and durable clinical benefit, which is prompting sponsors to incorporate health economics and outcomes research earlier in development. Taken together, these shifts indicate a maturing field where scientific innovation is increasingly paired with pragmatic, outcome-focused development pathways.

Assessing how recent United States tariff shifts have reshaped supply chain resilience, sourcing strategies, and commercial planning across liver fibrosis drug development

Recent tariff policy developments in the United States have introduced a layer of complexity to the global supply chains that underpin drug development and commercialization. Tariff adjustments affect both the procurement of active pharmaceutical ingredients and the sourcing of specialized biologics manufacturing inputs. Manufacturers that rely on cross-border component sourcing have needed to reassess supplier contracts, inventory strategies, and cost structures in order to preserve supply continuity and protect margins.

In response, many organizations have diversified their supplier base, reshored critical manufacturing steps, or expanded inventories of key raw materials to mitigate disruption. These operational shifts have also influenced outsourcing decisions and relationships with contract development and manufacturing organizations, prompting tighter collaboration and increased transparency around lead times and capacity constraints. Regulatory teams, in parallel, are managing the implications for product labeling, import documentation, and quality oversight when manufacturing footprints change.

Strategic pricing and reimbursement discussions have been affected as well, with commercial teams recalibrating launch strategies to account for potential increases in landed costs. Meanwhile, stakeholders across the value chain are placing higher priority on supply chain resilience, dual sourcing, and scenario planning. Collectively, these changes underscore the importance of integrating regulatory, operations, and commercial planning to maintain clinical momentum and ensure patient access amid evolving trade policies.

Multidimensional segmentation insights that connect drug class, mechanism of action, administration route, and distribution channels to inform development and commercialization strategy

Understanding segmentation is essential to aligning research and commercial strategies with therapeutic opportunity. When therapies are organized by drug class, the field spans biologic therapies, cell therapies, gene therapies, and small molecule inhibitors. Within the biologic category, attention centers on monoclonal antibodies and recombinant proteins as platforms that offer target specificity and modulated immune engagement, while small molecule inhibitors encompass both natural product-derived scaffolds and synthetically optimized compounds that enable oral dosing and intracellular target access.

Mechanism-based segmentation further refines prioritization by highlighting ASK1 inhibitors, galectin-3 inhibitors, PPAR agonists, and TGF beta blockers as distinct mechanistic approaches. The PPAR axis itself is subdivided into PPAR alpha, PPAR delta, and PPAR gamma, each presenting differentiated metabolic and fibrotic biology that can be matched to patient phenotypes and comorbidity profiles. Route of administration matters for adherence and chronic treatment planning; injectable therapies, administered either intravenously or subcutaneously, tend to support controlled pharmacokinetics and clinic-based dosing models, whereas oral formulations facilitate outpatient management and broader uptake.

Distribution channels influence commercial execution and patient access. Hospital pharmacies serve acute and inpatient settings where complex biologics and infusion therapies are delivered, online pharmacies enable convenience and continuity for stable chronic regimens, and retail pharmacies-comprising chain and independent outlets-drive outpatient dispensing and direct-to-patient accessibility. Together, these intersecting segmentation lenses offer a multidimensional framework to prioritize development, design clinical programs, and craft go-to-market strategies that reflect modality, mechanism, administration route, and distribution realities.

Regional development and access dynamics that shape regulatory engagement, evidence generation, and commercial execution across multiple global healthcare ecosystems

Regional dynamics exert a profound influence on development priorities, regulatory engagement, and commercial access pathways. In the Americas, regulatory agencies and payers emphasize real-world effectiveness and value-based contracting, which incentivizes sponsors to design evidence generation strategies that demonstrate durable clinical outcomes and cost-of-care impacts. Clinical networks and academic centers across the region also contribute to patient recruitment and biomarker validation efforts, shaping early-phase study design and translational research collaborations.

Across Europe, Middle East & Africa, regulatory harmonization efforts and varying healthcare delivery models require tailored approaches to clinical trial execution and market access planning. European regulatory pathways often prioritize comparability and demonstration of incremental benefit, while regional variations in health technology assessment processes mean that evidence packages must be calibrated to local payer expectations. In parts of the Middle East and Africa, constrained infrastructure and differing prevalence patterns influence the design of implementation studies and access programs.

The Asia-Pacific region presents diverse clinical and commercial environments, with strong capabilities in biologics manufacturing, growing clinical trial capacity, and rapid adoption of digital health tools. Country-specific regulations and reimbursement pathways necessitate early engagement with local stakeholders. Taken together, these regional contours underscore the need for adaptive regulatory strategies, culturally informed patient engagement, and evidence plans that align with payer and provider priorities across geographies.

How company strategies, partnerships, and platform capabilities are converging to drive differentiated pipelines and collaborative approaches in liver fibrosis therapeutics

Company strategies in liver fibrosis are characterized by a mix of platform-driven innovation, targeted product development, and strategic collaboration. Biotech firms are advancing differentiated mechanisms and first-in-class assets, leveraging nimble translational pipelines and focused patient-identification strategies. Larger pharmaceutical companies contribute scale, regulatory experience, and commercialization infrastructure, and increasingly seek partnerships with innovators to accelerate late-stage development and broaden therapeutic portfolios.

Contract research organizations and contract development and manufacturing organizations play a critical role in accelerating timelines and enabling flexible capacity for both biologics and small molecule programs. These partners support adaptive trial designs, complex supply chain coordination, and regulatory submissions across multiple jurisdictions. Strategic alliances, licensing agreements, and co-development deals are common as organizations combine strengths: scientific ingenuity from smaller developers paired with commercial and regulatory capabilities from established firms.

Across the competitive landscape, differentiation arises from clinical efficacy signals, safety profiles amenable to chronic administration, and the ability to demonstrate mechanistic engagement through validated biomarkers. Companies that integrate translational science, patient-centric trial designs, and robust commercial planning are positioned to navigate reimbursement complexities and stakeholder expectations more effectively. The emphasis on collaboration, rather than purely head-to-head competition, reflects the complexity of addressing fibrotic disease biology and the value of complementary capabilities.

Actionable strategic initiatives that align translational biomarkers, supply chain resilience, regional regulatory engagement, and partnership models to accelerate successful therapeutic launches

Industry leaders should prioritize a set of actionable initiatives that align scientific promise with operational and commercial realities. First, integrate translational biomarker strategies early to de-risk clinical programs and create clear links between mechanism of action and clinical endpoints. This alignment will facilitate regulatory dialogue and strengthen value propositions for payers. Second, invest in supply chain resilience by diversifying suppliers for critical inputs, evaluating regional manufacturing options, and establishing contingency plans that preserve clinical and commercial continuity.

Third, pursue strategic collaborations that combine complementary capabilities: emerging innovators should seek partners for late-stage development and commercialization, while established companies can accelerate innovation through targeted licensing and co-development agreements. Fourth, tailor regional strategies to local regulatory and payer landscapes, engaging health technology assessment bodies and regional clinical networks to ensure evidence packages meet local requirements. Finally, design commercial models that reflect route of administration and distribution dynamics: ensure appropriate clinic-based support for injectable therapies and frictionless retail and online fulfillment for oral regimens.

By executing these recommendations, organizations can translate scientific advances into durable clinical impact while managing operational complexity and aligning stakeholder incentives across development and commercialization pathways.

A rigorous mixed-methods research approach combining expert primary interviews, systematic secondary literature review, and operational analysis to validate therapeutic and commercial insights

The research behind this report combines multiple methodological approaches to ensure a robust and evidence-based perspective. Primary research included structured interviews with clinical experts in hepatology, regulatory advisors, industry executives, and supply chain specialists to capture current practice patterns, regulatory expectations, and operational constraints. These qualitative insights were synthesized to contextualize therapeutic differentiation and to illuminate decision points that influence development and commercialization strategies.

Secondary research encompassed a systematic review of peer-reviewed literature, clinical trial registries, and publicly available regulatory guidance to map mechanistic rationales, clinical endpoints, and translational biomarkers. Operational analysis leveraged industry reports on manufacturing capabilities, supply chain frameworks, and distribution models to assess practical implications for development and market entry. Throughout the process, triangulation of evidence was applied to validate conclusions and to ensure that interpretations reflected multiple perspectives.

Analytical rigor was maintained through iterative validation with subject matter experts and cross-functional reviewers. The methodology prioritized clarity and reproducibility, with an emphasis on linking mechanistic science to clinical trial design and commercial execution. This approach supports decision-makers seeking actionable intelligence grounded in both scientific evidence and operational feasibility.

A conclusive synthesis highlighting actionable priorities across science, clinical development, operations, and commercial execution to realize durable therapeutic impact in liver fibrosis

In summary, the liver fibrosis therapeutic landscape is transitioning from conceptual promise to pragmatic execution. Scientific advances in target biology and modality engineering have expanded the set of viable interventions, while innovations in diagnostics and trial design are enabling more efficient proof-of-concept work. At the same time, operational pressures-ranging from supply chain shifts to tariff-related sourcing considerations-require integrated planning across R&D, manufacturing, and commercial teams.

Success in this environment will hinge on the ability to align mechanistic clarity with translational biomarkers, to design patient-centric clinical programs that reflect route of administration and distribution realities, and to engage payers and regulators early with robust evidence strategies. Strategic collaborations and adaptive operational models will be key enablers, allowing organizations to combine scientific differentiation with scale and market access expertise.

The outcome-oriented approach advocated throughout this report emphasizes measurable clinical benefit, durable patient outcomes, and pragmatic pathways to access. Stakeholders that adopt data-driven development, prioritize supply chain resilience, and pursue partnerships that complement internal capabilities will be best positioned to convert scientific innovation into sustained clinical and commercial success.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Liver Fibrosis Drugs Market, by Drug Class

• 8.1. Biologic Therapies
  • 8.1.1. Monoclonal Antibodies
  • 8.1.2. Recombinant Proteins
• 8.2. Cell Therapies
• 8.3. Gene Therapies
• 8.4. Small Molecule Inhibitors
  • 8.4.1. Natural Products
  • 8.4.2. Synthetic Compounds

9. Liver Fibrosis Drugs Market, by Mechanism Of Action

• 9.1. ASK1 Inhibitors
• 9.2. Galectin-3 Inhibitors
• 9.3. PPAR Agonists
  • 9.3.1. PPAR Alpha
  • 9.3.2. PPAR Delta
  • 9.3.3. PPAR Gamma
• 9.4. TGF Beta Blockers

10. Liver Fibrosis Drugs Market, by Route Of Administration

• 10.1. Injectable
  • 10.1.1. Intravenous
  • 10.1.2. Subcutaneous
• 10.2. Oral

11. Liver Fibrosis Drugs Market, by Distribution Channel

• 11.1. Hospital Pharmacy
• 11.2. Online Pharmacy
• 11.3. Retail Pharmacy
  • 11.3.1. Chain Pharmacy
  • 11.3.2. Independent Pharmacy

12. Liver Fibrosis Drugs Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Liver Fibrosis Drugs Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Liver Fibrosis Drugs Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Liver Fibrosis Drugs Market

16. China Liver Fibrosis Drugs Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Akero Therapeutics, Inc.
• 17.6. AstraZeneca plc
• 17.7. BioLineRx Ltd.
• 17.8. Boehringer Ingelheim International GmbH
• 17.9. Bristol-Myers Squibb Company
• 17.10. FibroGen, Inc.
• 17.11. Galectin Therapeutics, Inc.
• 17.12. Galmed Pharmaceuticals Ltd.
• 17.13. Gilead Sciences, Inc.
• 17.14. Hepion Pharmaceuticals, Inc.
• 17.15. Intercept Pharmaceuticals, Inc.
• 17.16. Inventiva S.A.
• 17.17. Ionis Pharmaceuticals, Inc.
• 17.18. Johnson & Johnson Services, Inc.
• 17.19. Madrigal Pharmaceuticals, Inc.
• 17.20. Merck & Co., Inc.
• 17.21. Novartis AG
• 17.22. Novo Nordisk A/S
• 17.23. Pfizer Inc.
• 17.24. Zydus Lifesciences Ltd.